---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-035067"
form_type: "8-K"
ticker: null
cik: "0001845459"
company_name: "NKGen Biotech, Inc."
filed_at: "2024-03-15T23:59:59+00:00"
generated_at: "2026-06-04T17:52:51.294842+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NKGen Biotech receives Nasdaq MVLS deficiency notice; 180-day cure period until Sep 9, 2024

## Summary
- Received Nasdaq Staff notice on March 11, 2024, for MVLS below $50M minimum for 30 consecutive business days.
- Must regain compliance by Sep 9, 2024; if MVLS >= $50M for 10 consecutive business days, notice will be closed.
- Company's market cap exceeded $50M on March 11, 2024 after the notice; evaluating actions to regain compliance.
- If not compliant by Sep 9, common stock may be delisted; company may appeal or apply to transfer to Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001104659-24-035067
- form_type: 8-K
- cik: 0001845459
- company_name: NKGen Biotech, Inc.
- filed_at: 2024-03-15T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845459/000110465924035067/0001104659-24-035067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845459/000110465924035067/tm248953d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-035067
- JSON: https://secwatch.observer/filing/0001104659-24-035067.json
- Plain text: https://secwatch.observer/filing/0001104659-24-035067.txt

## Key facts
- Listing & Compliance Notices
  NKGen Biotech, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(A), 5810(c)(3)(C)
  source text: March 11, 2024, NKGen Biotech, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days prior to the date of the Notice, the Company’s Market Value of Listed Securities (as defined under Nasdaq rules) was below the minimum of $50 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000110465924035067/0001104659-24-035067-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.